BI 6727
BI 6727 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Clinical Trials (7)
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7